Patient-Centric & Prospective Medicine Project

The Center for Medicine in the Public Interest (CMPI) has initiated a research program to study the treatment preferences of patients with Idiopathic pulmonary fibrosis (IPF). The project is supported by Intermune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Dr. John F P Bridges PhD, an Associate Professor at the Johns Hopkins Bloomberg School of Public Health and Senior Fellow at CMPI, will serve as the principal investigator of this project. The project will apply the principles of community-based participatory medicine to engage patients, family members, providers and other stakeholder in the design and pilot of a survey instrument to measure the stated-preferences of patients of with IPF for the potential benefits and risk of therapy. A geographically diverse sample of patients with IPF will be then recruited through clinics and advocacy groups to complete the survey. Analysis will use state-of-the-art methods to estimate preferences and results will be disseminated widely.
Sign Up for Our Email Newsletter

RECENT NEWS

War on Vaping Threatens Public Health

War on Vaping Threatens Public Health

Will the government hamstring what is potentially the most important public health innovation of the 21st century?...  Read more

PBMs Are Hogging Our Drug Discounts

PBMs Are Hogging Our Drug Discounts

PBMs are knowingly profiting off the backs of American patients, pharmacists, and innovators....  Read more

Advancing 21st Century Pain Management Conference (August 17, 2018)

Advancing 21st Century Pain Management Conference (August 17, 2018)

CMPI conference: Advancing 21st Century Pain Management Keynote Speaker: FDA Commissioner Scott Gottlieb...  Read more

DRUGWONKS BLOG